Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Katherine L. Nathanson, MD

Katherine L. Nathanson, MD Physician

Professor of Medicine
Professor of Genetics

Languages spoken:

  • French

Dr. Nathanson is a Penn Medicine employed physician.

Clinical Specialties

Specialty:

  • Medicine
    • Medical Genetics

Programs & Centers:

Board Certification:

  • Medical Genetics, 1999

Clinical Expertise:

  • Acoustic Neuromas
  • Birt-Hogg-Dubé Syndrome
  • Cancer Genetic Testing
  • Genetic and Rare Diseases Treatments and Procedures
  • Genetic Counseling
  • Genetic Skin Disorders
  • Genetic Testing
  • Hereditary Cancer Syndrome
  • Hereditary Papillary Renal Cancer
  • Klinefelter Syndrome
  • Li-Fraumeni Syndrome
  • Neurofibromatosis Type 1 (NF1)
  • Paragangliomas
  • Pheocromocytoma
  • Schwannomatosis
  • Tuberous Sclerosis
  • Von Hippel Lindau Syndrome (VHL)

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Beth Israel Deaconess Medical Center
Fellowship: Children's Hospital of Philadelphia

Memberships

American Association for Cancer Research, National American Association for the Advancement of Science, National American College of Medical Genetics, National American College of Physicians, National American Society for Clinical Investigation, National American Society for Human Genetics, National Breast Cancer Information Core Steering Committee, National Melanoma Research Breakthrough Consortium, National Movember GAP5 Translational Research Steering Committee (Testicular Cancer), International National Cancer Institute Blue Ribbon Panel Working Group - Tumor Evolution and Progression, National National Institutes of Health, Cancer Genetics Study Section, National National Institutes of Health, National Cancer Institute Loan Repayment Program Study Section, National TCGA Pheochromocytoma/Paraganglioma Disease Working Group, National TCGA Testicular Germ Cell Tumor Working Group, National Cancer Institute, National Tuberous Sclerosis Alliance, National

Hospital Affiliation

Dr. Nathanson is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Dr. Nathanson’s research focuses on the genetics of human cancer, both germline changes which confer susceptibility to cancer and somatic genetic changes associated with outcome.

Her research projects fall into several areas:

1) Identification and characterization of germline genetic changes associated with breast cancer susceptibility. These projects utilize two sample sets, a large clinical database of high risk breast cancer patients and a case-control study of white and black patients with breast cancer. Currently the projects in the laboratory focus on resequencing of BRCA1-associated genes as candidate breast cancer susceptibility genes in patients with high risk breast cancer and studying copy number variation as associated with potential susceptibility to high risk breast cancer in families with multiple cases of breast cancer.

2) Identification of genetic changes associated with testicular cancer susceptibility in case-control sample set. Dr. Nathanson recently completed a successful genome wide association study in testicular cancer, and is in the process of designing and doing a number of follow-up studies.

3) Identification of somatic genetic markers in melanoma as determinants of response to therapy. The projects in the laboratory focus on several aspects of melanoma genetics including genotyping patients to determine targeted therapy selection, using genetics and genomics to sub-set melanomas, as well as understand response to therapy, and identify novel genes important in melanoma progression.

Selected Publications:

Scelo G, Hofmann JN, Banks RE, Bigot P, Bhatt RS, Cancel-Tassin G, Chew SK, Creighton CJ, Cussenot O, Davis IJ, Escudier B, Frayling TM, Häggström C, Hildebrandt MA, Holcatova I, Johansson M, Linehan WM, McDermott DF, Nathanson KL, Ogawa S, Perlman EJ, Purdue MP, Stattin P, Swanton C, Vasudev NS, Wu X, Znaor A, Brennan P, Chanock SJ: International cancer seminars - A focus on kidney cancer. Ann Oncol 27 (8): 1382-1385,2016.

Hart SN, Maxwell KN, Thomas T, Ravichandran V, Wubberhorst B, Klein RJ, Schrader K, Szabo C, Weitzel JN, Neuhausen SL, Nathanson K, Offit K, Couch FJ, Vijai J: Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. Brief Bioinform 17 (4): 672-677,2016.

Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A, Bonanni B, Brewer C, Caldes T, Caligo MA, Campbell I, Chan SB, Claes KB, Cohn DE, Cook J, Daly MB, Damiola F, Davidson R, Pauw A, Delnatte C, Diez O, Domchek SM, Dumont M, Durda K, Dworniczak B, Easton DF, Eccles D, Edwinsdotter Ardnor C, Eeles R, Ejlertsen B, Ellis S, Evans DG, Feliubadalo L, Fostira F, Foulkes WD, Friedman E, Frost D, Gaddam P, Ganz PA, Garber J, Ga: Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One 11 (7): e0158801,2016.

Qian F, Feng Y, Zheng Y, Ogundiran TO, Ojengbede O, Zheng W, Blot W, Ambrosone CB, John EM, Bernstein L, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press MF, Nathanson KL, Hennis A, Nemesure B, Ambs S, Kolonel LN, Olopade OI, Haiman CA, Huo D: Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Hum Genet : 2016.

Shannan B, Watters A, Chen Q, Mollin S, Dörr M, Meggers E, Xu X, Gimotty PA, Perego M, Li L, Benci J, Krepler C, Brafford P, Zhang J, Wei Z, Zhang G, Liu Q, Yin X, Nathanson KL, Herlyn M, Vultur A: PIM kinases as therapeutic targets against advanced melanoma. Oncotarget : 2016.

Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, Ghoussaini M, Kar S, Freeman A, Hopper JL, Milne RL, Bolla MK, Wang Q, Dennis J, Agata S, Ahmed S, Aittomäki K, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Arun BK, Arver B, Bacot F, Barrowdale D, Baynes C, Beeghly-Fadiel A, Benitez J, Bermisheva M, Blomqvist C, Blot WJ, Bogdanova NV, Bojesen SE, Bonanni B, Borresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Broeks A, Brüning T, Burwinkel B, Buys SS, Cai Q, Caldes T: Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18 (1): 64,2016.

Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM Jr, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND.: Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncol : 2016.

Jean S, Li J, Katsarosc D, Wubbenhorst B, Maxwell KN, Fishbein L, McLaneg MW, Benedettod C, Canutod EM, Mitra N, Zhang L, Nathanson KL*, Tanyi JL*: Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations Oncotarget : 2016.

Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A; Australian Ovarian Cancer Study Group, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Be: No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141 (2): 386-401,2016.

Maxwell KN, Hart SN, Vijai J, Schrader KA, Slavin TP, Thomas T, Wubbenhorst B, Ravichandran V, Moore RM, Hu C, Guidugli L, Wenz B, Domchek SM, Robson ME, Szabo C, Neuhausen SL, Weitzel JN, Offit K, Couch FJ, Nathanson KL: Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-cancer - Associated Genes in Families Affected by Breast Cancer. Am J Hum Genet 98 (5): 801-17,2016.

Academic Contact Info

351 BRB II/III
421 Curie Blvd
University of Pennsylvania

Philadelphia, PA 19104
Phone: (215) 662-4740
Patient appointments: 800-789-PENN (7366)

Related Links